BioDelivery Sciences International   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Raleigh NC United States (1997)
Status: Acquired by Collegium Pharmaceutical, Inc. (2022)

Organization Overview

First Clinical Trial
2006
NCT00293020
First Marketed Drug
2009
fentanyl (Innovar)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BDSI | BioDelivary Sciences Internantional, Inc. | BioDelivery Sciences International

Active Ingredients

Marketed Drugs (5)

buprenorphine (2014)

celecoxib (celebrex) (2020)

fentanyl (Innovar) (2009)

naldemedine (symproic) (2017)

naloxone (narcan) (2014)

Drugs in Phase 4 Trials (1)

buprenorphine (13 trials)

Drugs in Phase 3 Trials (2)

fentanyl (Innovar) (3 trials)

naloxone (narcan) (1 trial)

Drugs in Phase 2 Trials (3)

clonidine (catapres) (3 trials)

morphine (1 trial)

oxycodone (oxycontin) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Breakthrough Pain (Phase 3)

Chronic Pain (Phase 3)

Diabetic Neuropathies (Phase 2)

Low Back Pain (Phase 3)

Neuralgia (Phase 3)

Opioid-Related Disorders (Phase 3)

Osteoarthritis (Phase 3)

Pain (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Respiratory Insufficiency (Phase 3)

Toothache (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 6